Research Topic

Recent Advances in the Pathogenesis and Therapy of Chronic Hepatitis B with Acute Exacerbation

About this Research Topic

Around 400 million Hepatitis B virus carriers are estimated in the world. Hepatitis B virus infection may lead to Chronic Hepatitis B (CHB) disease. Acute Exacerbation (AE) of CHB is characterized by impairment of liver function following the rise of the virus DNA and has been reported to have a cumulative incidence of 10%-30% every year. AE can also develop in CHB patients who received cytotoxic chemotherapy or immunomodulatory agents.

CHB with AE can be mild, but some patients may develop a severe course such as hepatic decompensation and even mortality. The underlying pathogenesis is not quite clear but is usually attributed to the activation of T lymphocyte-mediated immune response targeting HBV.

Whether the antiviral treatment for CHB with severe AE improves clinical outcome remains controversial but some nucleo(s)tide analogs (NUCs) have been used in the treatment of this disease. Nevertheless, there is a lack of randomized controlled studies that compare the effects of different NUCs in the CHB with severe AE treatment.

With the above in mind, the scope of this Research Topic is to expand our knowledge regarding the natural history, pathogenic mechanisms, prognostic factors, and therapeutic options of CHB with AE.
We welcome Review Articles, Original Research, Brief research Reports, Clinical Trials, which investigate the following research questions:

• Pathogenetic mechanisms of CHB with AE
• Natural history of CHB with AE with or without NUCs treatment
• Prognostic factors associated with CHB with AE.
• Therapeutic benefits of different NUCs alone or in combination for CHB with AE
• Clinical outcome of NUCs withdrawal AE
• Therapeutic options for the prevention of AE in CHB undergoing cytotoxic chemotherapy or immuno-modulatory agents


Keywords: Hepatitis B, Acute exacerbation, Nucleos(t)ide analogue, chemotherapy


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Around 400 million Hepatitis B virus carriers are estimated in the world. Hepatitis B virus infection may lead to Chronic Hepatitis B (CHB) disease. Acute Exacerbation (AE) of CHB is characterized by impairment of liver function following the rise of the virus DNA and has been reported to have a cumulative incidence of 10%-30% every year. AE can also develop in CHB patients who received cytotoxic chemotherapy or immunomodulatory agents.

CHB with AE can be mild, but some patients may develop a severe course such as hepatic decompensation and even mortality. The underlying pathogenesis is not quite clear but is usually attributed to the activation of T lymphocyte-mediated immune response targeting HBV.

Whether the antiviral treatment for CHB with severe AE improves clinical outcome remains controversial but some nucleo(s)tide analogs (NUCs) have been used in the treatment of this disease. Nevertheless, there is a lack of randomized controlled studies that compare the effects of different NUCs in the CHB with severe AE treatment.

With the above in mind, the scope of this Research Topic is to expand our knowledge regarding the natural history, pathogenic mechanisms, prognostic factors, and therapeutic options of CHB with AE.
We welcome Review Articles, Original Research, Brief research Reports, Clinical Trials, which investigate the following research questions:

• Pathogenetic mechanisms of CHB with AE
• Natural history of CHB with AE with or without NUCs treatment
• Prognostic factors associated with CHB with AE.
• Therapeutic benefits of different NUCs alone or in combination for CHB with AE
• Clinical outcome of NUCs withdrawal AE
• Therapeutic options for the prevention of AE in CHB undergoing cytotoxic chemotherapy or immuno-modulatory agents


Keywords: Hepatitis B, Acute exacerbation, Nucleos(t)ide analogue, chemotherapy


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

26 January 2021 Abstract
26 May 2021 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

26 January 2021 Abstract
26 May 2021 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..